• Revenue: SEK 64.2 million for Q4 2024, up from SEK 45.5 million in Q4 2023 and SEK 48.7 million in Q3 2024.
• Quarterly Growth: 41.5% increase in Q4 2024.
• Full Year Sales: SEK 190 million for 2024.
• Gross Margin: Close to 85% in Q4 2024, just below 80% for the full year.
• EBIT: SEK 0.7 million positive in Q4 2024.
• Cash Position: SEK 145 million at year-end 2024.
• Direct Sales: 65% of total revenue in 2024, down from 77% in 2023.
• EMEA Growth: 33% increase in Q4 2024 compared to Q4 2023.
• North and South America Growth: Similar pace to Europe, contributing to full year sales.

• Warning! GuruFocus has detected 6 Warning Signs with FRA:OL0.

Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Devyser Diagnostics AB (FRA:OL0) reported its first profitable quarter as a public company in Q4 2024.
• Revenue for Q4 2024 increased by 41.5% compared to the same quarter last year, reaching SEK 64.2 million.
• The company has a strong partnership with Thermo Fisher, which resulted in the largest order in the company's history during Q4.
• Devyser's gross margins improved to close to 85% in Q4, indicating strong operational efficiency.
• The company has a clear strategy to focus on two customer segments: clinical genetics labs and transplantation labs, aiming to become a leading partner in these fields.

Negative Points

• Direct sales decreased as a result of transitioning customers to Thermo Fisher, impacting revenue distribution.
• APAC region experienced a small decline in growth, contrasting with other regions' performance.
• The company had to make a provision for an Italian payback fee, which negatively impacted EBIT.
• Inventory buildup from Thermo Fisher in Q4 may affect purchasing patterns in early 2025.
• Capitalized R&D expenses nearly doubled year-over-year, which could impact short-term profitability.

Q & A Highlights

Q: Can you quantify the impact of transitioning customers to Thermo Fisher on direct sales and the growth rate excluding transplant tests? A: We cannot fully quantify this, but the transition involved handing over exclusive customers for Chimerism to Thermo Fisher, which affected direct sales. The overall growth has not been specifically commented on, but the transition is part of a strategic move to enhance market reach. - Theis Kipling, Chief Commercial Officer

Q: What will the large order from Thermo Fisher be used for, and is there a boost from initial validation batches? A: The order will be used for clinical diagnostics, validation, and onboarding new customers, not limited to Europe. It includes demoing and providing existing customers with clinical routine supplies. - Theis Kipling, Chief Commercial Officer

Q: How should we interpret the extended agreement with CIE and its impact on North American sales? A: The agreement will significantly increase direct sales in North America, doubling revenues in 2025 compared to 2024. However, specific numbers are not disclosed. - Theis Kipling, Chief Commercial Officer

Q: Is there a risk that Thermo Fisher's inventory build-up will affect sales in Q2 and Q3? A: The impact is expected in Q1 and possibly parts of Q2, but there is no indication of softness for the year. The inventory strategy is designed to support business acceleration. - Theis Kipling, Chief Commercial Officer

Q: Can you provide guidance on capitalized R&D and its impact on profitability? A: The increase in R&D is due to efficiencies and new office processes. While it won't double year-over-year as it did from 2023 to 2024, a strong focus on R&D and profitability will continue. - Sabina Berlin, Chief Financial Officer

For the complete transcript of the earnings call, please refer to the full earnings call transcript.